CYP2D6 has been suggested to be functionally similar to the dopamine transporter. The present study was aimed at analysing the frequency of CYP2D6 alleles and genotype among schizophrenic patients compared to healthy volunteers. CYP2D6 *3, *4, *5, *6, *10 and duplicated alleles were analysed in 128 unselected schizophrenia inpatients (SP) and 142 unrelated white European Spanish healthy volunteers (HV). SP and HV with 42, 2, 1 or 0 CYP2D6 active genes were 4.7, 64.8, 28.1 and 2.3%, and 6.3, 52.1, 33.1 and 8.5%, respectively. The frequency of homozygous for CYP2D6 inactive alleles or poor metabolizers (PMs) was lower (Po0.05) in SP than in HV. Furthermore, the frequency of CYP2D6 inactive alleles was also lower in SP than in HV (16.8 vs 25.7; Po0.05), specifically the CYP2D6*6 allele was not found among patients. The present study shows a lower frequency of PMs in schizophrenic patients than in healthy volunteers supporting the hypothesis of a potential role of CYP2D6 in the vulnerability to schizophrenia.
Introduction
Cytochrome P450 (CYP) enzymes are involved in the metabolism of different xenobiotics and several clinically important drugs. 1 It is known that CYP2D6 is involved in the metabolism of several psychotropic drugs, 2 and we have shown it to influence the plasma concentration of antipsychotics (haloperidol, thioridazine, risperidone and so on) and their relevance for QTc interval lengthening. [3] [4] [5] [6] [7] The expression of CYP2D6 enzyme has been described not only in the liver but also in other tissues such as the brain, where it is localized in the pyramidal cells of the cortex and hippocampus (CA1-3) and the Purkinje cells of the cerebellum. 8, 9 CYP2D6 activity has also been related to personality traits (psychic anxiety, psychasthaenia, inhibition of aggression, and socialization), which suggested that CYP2D6 enzyme may have an endogenous neuroactive substrate or product, such as a biogenic neurotransmitter amine. 10 The CYP2D6 gene is highly polymorphic with alleles causing absent poor metabolizers (PMs), decreased, normal extensive metabolizers (EMs) and increased activity ultrarapid metabolizers (UMs) owing to the presence of two or more copies of a functional CYP2D6 allele existing in tandem on the same chromosome. Despite more than 50 different CYP2D6 allelic variants have been identified (www.imm.ki.se/CYPalleles/cyp2d6.htm), analyses of only the CYP2D6*3, CYP2D6*4, CYP2D6*4x2, CYP2D6*5 and CYP2D6*6 mutant alleles (abolished activity) and gene duplications of CYP2D6*1 and CYP2D6*2 (increased activity) have allowed a 99% sensitive prediction of PM or UM status, respectively, in WhiteEuropean and White-American populations. 11 The CYP2D6*10 allele is associated with decreased CYP2D6 activity and is particularly common in Chinese and Japanese populations.
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Association studies between CYP2D6 and schizophrenia have found no association, [13] [14] [15] [16] [17] which can be partly explained by the fact that only two or three defective CYP2D6 alleles (*3, *4 and/or *10) were analysed. However, other studies have shown an under-representation of PMs in schizophrenia patients. 18, 19 Therefore, the present study was aimed at analysing whether there is a lower frequency of CYP2D6 PMs among schizophrenia patients than in healthy volunteers.
Results
The percentages of schizophrenic patients with 42, 2, 1 or 0 CYP2D6 active genes were 4.7, 64.8, 28.1 and 2.3%, respectively. In healthy volunteers these percentages were 6.3, 52.1, 33.1 and 8.5% (Table 1 ). The frequency of individuals homozygous for CYP2D6-inactive alleles (*3, *4, *4 Â 2, *5 or *6) or PMs was lower in schizophrenic patients (Po0.05) than in healthy volunteers. Furthermore, the frequency of CYP2D6 inactive alleles was also lower in schizophrenic patients than in healthy volunteers (16.8 vs 25.7; Po0.05). A list of the allele combinations is presented in Table 1 . The frequencies of CYP2D6 alleles were similar in schizophrenics and healthy volunteers except for the CYP2D6*6 allele, which was not found among patients.
Discussion
The present study was aimed at analysing whether CYP2D6 PM schizophrenic patients were under-represented in comparison to healthy volunteer PMs. The present results are in agreement with those of Brockmoller et al. 18 during the study of the relevance of CYP2D6 genotype for haloperidol efficacy. Those workers reported in this study and in some previous unpublished data a lower frequency of PMs in schizophrenic patients than in healthy volunteers (2.9 vs 7%), similar to the findings of the present study (2.3 vs 8.5%). 18 The present frequency of PMs in this healthy volunteer population is within the range of the expected frequency of PMs in Caucasian healthy volunteers, which is about 7-10% including Spaniards as we have previously reported for 925 subjects. 10 Other studies have also reported the same underrepresentation of PMs in large samples of schizophrenia patients. 19 Accordingly, it might be expected to find a higher frequency of CYP2D6 gene duplications in schizophrenia patients than in controls, which it was difficult to see in the present relatively small sample size. Patients were selected only by diagnosis, thus a population selection bias cannot be ruled out. Further studies with a higher number of patients will be necessary to replicate the present results.
There have been other studies, which did not find these differences between the observed and expected frequency of CYP2D6 PMs in schizophrenic patients. [13] [14] [15] [16] [17] Yet, these studies should be interpreted with caution as they only analysed two or three defective CYP2D6 variant alleles (*3, *4 and/or *10) as causing PM status, and/or used a diverse control group, that is non-psychotics. 17 The differences found in the present study in the allele distribution between schizophrenic patients and healthy volunteers cannot be explained by ethnicity, because both populations were White-Europeans from the same region of Spain. Differences cannot be explained by the genotyping method either as the method used was the same for both populations. 20 A possible explanation for the differences found would be the involvement of CYP2D6 in the brain metabolism of a neuroactive substrate that may contribute to the vulnerability, clinical severity and treatment outcome of schizophrenia.
The potential role of CYP2D6 in cerebral drug metabolism may be indirectly supported by the report of a greater efficacy and lower side effects of haloperidol treatment in CYP2D6 PM schizophrenia patients than in UMs, despite their presenting similar drug plasma concentrations (6.974.8 and 775.7 mg/l, respectively). 18 Also, there is evidence for the involvement of CYP2D6 not only in drug metabolism but also in the endogenous metabolism. We first suggested a role of CYP2D6 in the metabolism of endogenous psychoactive substrates or products, hypothesizing its participation in the metabolism of some neuroactive amine and a possible influence on genderrelated factors. 1, 10 Later CYP2D6 was reported to be involved in the biotransformation of several neurotransmitters functionally impaired in psychiatric disorders including schizophrenia, such as dopamine, serotonin and neuroactive steroids. [21] [22] [23] In view of the present findings, our hypothesis is that CYP2D6 is associated not only with interindividual variability in the response to antipsychotic drugs, but also with the vulnerability to psychiatric disorders such as schizophrenia.
Further studies with larger samples of inpatients and outpatients are warranted to confirm the under-representation of PMs in schizophrenia and the potential role of CYP2D6 in the vulnerability to this illness and drug response.
Methods and materials
Patients and healthy volunteers A group of 128 (112 males/16 females) White-European Spanish schizophrenia patients (DSM-IV criteria) without any relevant organic disease were included in the study. They were inpatients at Mérida Psychiatric Hospital (Extremadura, Spain). A group of 142 (71 males/71 females) unrelated White European Spanish healthy volunteers from the same geographical area were also included for comparisons of CYP2D6 allele and genotype frequencies. A routine clinical examination was performed and the medical history was taken before the study. The subjects were informed about the aims of the study and gave their consent to participate. The study was performed according to the Helsinki Declaration and was approved by the Ethics Committee of the Extremadura University Hospital.
CYP2D6 genotyping
For CYP2D6 genotyping, 10 ml blood samples were collected in ethylenediamintetra acetic acid tubes, and DNA was extracted using the QIAamp DNA blood kit (QIAGEN, Hilden, Germany). The CYP2D6 genotype was analysed by PCR and PCR-RFLP techniques used in our laboratory for the CYP2D6 *3, *4, *5, *6, *10 *17 and duplicated alleles. 20 
Data analysis
Genotype and allele frequencies were compared between schizophrenic patients and healthy volunteers by the two-tailed Fisher's test using GraphPad QuickCalcs (GraphPad Software Inc.). P-values o0.05 were regarded as statistically significant.
